120 related articles for article (PubMed ID: 30790564)
1. Development of a kinetic antibody-dependent cellular cytotoxicity assay.
Kamen L; Thakurta T; Myneni S; Zheng K; Chung S
J Immunol Methods; 2019 May; 468():49-54. PubMed ID: 30790564
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
3. A novel method for determining antibody-dependent cellular phagocytosis.
Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
[TBL] [Abstract][Full Text] [Related]
4. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
5. Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region.
González-González E; Camacho-Sandoval R; Jiménez-Uribe A; Montes-Luna A; Cortés-Paniagua I; Sánchez-Morales J; Muñoz-García L; Tenorio-Calvo AV; López-Morales CA; Velasco-Velázquez MA; Pavón L; Pérez-Tapia SM; Medina-Rivero E
J Immunol Methods; 2019 Jan; 464():87-94. PubMed ID: 30395815
[TBL] [Abstract][Full Text] [Related]
6. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
7. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
[TBL] [Abstract][Full Text] [Related]
8. Development of a simple new flow cytometric antibody-dependent cellular cytotoxicity (ADCC) assay with excellent sensitivity.
Tanaka M; Ishige A; Yaguchi M; Matsumoto T; Shirouzu M; Yokoyama S; Ishikawa F; Kitabayashi I; Takemori T; Harada M
J Immunol Methods; 2019 Jan; 464():74-86. PubMed ID: 30389576
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
10. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
12. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
13. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.
Miller ML; Finn OJ
Methods Enzymol; 2020; 632():431-456. PubMed ID: 32000909
[TBL] [Abstract][Full Text] [Related]
15. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Tóth G; Szöllősi J; Vereb G
Cytometry A; 2017 Oct; 91(10):1021-1029. PubMed ID: 28945315
[TBL] [Abstract][Full Text] [Related]
16. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
17. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.
Schiller CB; Braciak TA; Fenn NC; Seidel UJ; Roskopf CC; Wildenhain S; Honegger A; Schubert IA; Schele A; Lämmermann K; Fey GH; Jacob U; Lang P; Hopfner KP; Oduncu FS
Oncotarget; 2016 Dec; 7(50):83392-83408. PubMed ID: 27825135
[TBL] [Abstract][Full Text] [Related]
18. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
[TBL] [Abstract][Full Text] [Related]
19. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.
Wu Y; Li JJ; Kim HJ; Liu X; Liu W; Akhgar A; Bowen MA; Spitz S; Jiang XR; Roskos LK; White WI
AAPS J; 2015 Nov; 17(6):1417-26. PubMed ID: 26205082
[TBL] [Abstract][Full Text] [Related]
20. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]